Preclinical study of safety and neuroprotective efficacy of intranasal NEUROSTAT-NP in a rat model of chronic glaucoma

Glaucoma is the main cause of irreversible blindness. Despite reaching the target level of intraocular pressure (IOP), glaucoma often progresses. This highlights the urgent need for therapy aimed directly at protecting the optic nerve. This study presents the development and comprehensive preclinical evaluation of a novel drug, NEUROSTAT-NP – a dry intranasal powder for direct neuroprotection. The active ingredient, bromocriptine mesylate at an ultra-low dose of 0.3 mg, selectively activates dop